New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
Emerging data suggest women with endometriosis face a higher risk of postpartum depression and anxiety, underscoring the need for proactive screening and individualized care.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
This study uncovers how trauma, isolation, loss of identity, and lack of support can overlap and amplify each other, deepening despair and driving suicide risk among women in the perinatal period.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
In a recent study from Mass General Hospital, researchers examined whether information included in the medical record at the time of discharge after delivery could help us to identify individuals at increased risk for postpartum depression.
